Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the Copenhagen Stock Exchange as the company’s outlook remains clouded by ...

Danish pharmaceutical firm Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, announced Wednesday a 32 percent increase in net profit for the second ...

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

The popularity of Novo Nordisk's anti-diabetes and weight-loss treatments Ozempic and Wegovy had once made it a darling of ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...